Bodyl A Brand, Janna N de Boer, Sebastianus B J Oude Ophuis, Margot I E Slot, Bieke De Wilde, Kirsten C E E R Catthoor, Angelique J Goverde, P Roberto Bakker, Machteld C Marcelis, Koen P Grootens, Jurjen J Luykx, Sophie M Heringa, Cynthia Shannon Weickert, Iris E C Sommer, Thomas W Weickert
Although acute psychotic symptoms are often reduced by antipsychotic treatment, many patients with schizophrenia are impaired in daily functioning due to the persistence of negative and cognitive symptoms. Raloxifene, a Selective Estrogen Receptor Modulator (SERM) has been shown to be an effective adjunctive treatment in schizophrenia. Yet, there is a paucity in evidence for raloxifene efficacy in men and premenopausal women. We report the design of a study that aims to replicate earlier findings concerning the efficacy of raloxifene augmentation in reducing persisting symptoms and cognitive impairment in postmenopausal women, and to extend these findings to a male and peri/premenopausal population of patients with schizophrenia...
December 2020: Contemporary Clinical Trials Communications